Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) · Sponsor: Wuhan Createrna Science and Technology Co., Ltd
This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.
This description comes directly from the study's public registry record.
Wuhan Createrna Science and Technology Co.,Ltd · 027-68788900 · lcyxzx@createrna.com
Always discuss trial participation with your own doctor first.
| Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06933914